Subcutaneous nodule 18 (4%) 0 Injection-site pruritus 15 (3%) 1 (<1%) Injection-site erythema 10 (2%) 3 (<1%) Nodule 12 (3%) 0 Patients with one or more serious  adverse events13 (3%) 7 (2%) Discontinuations because of adverse events Nausea 1 (<1%) 9 (2%) Vomiting 1 (<1%) 4 (<1%) Diarrhoea 1 (<1%) 3 (<1%) Abdominal pain 2 (<1%) 0 Dyspepsia 0 2 (<1%) Gastroenteritis 0 1 (<1%) Asthenia 0 1 (<1%) Blood amylase increase 1 (<1%) 0 Brain stem infarction 0 1 (<1%) Acute cholecystitis 1 (<1%) 0 Decreased appetite 0 1 (<1%) Fatigue 0 1 (<1%) Gastritis 0 1 (<1%) Injection-site nodule 1 (<1%) 0 Myocardial infarction 1 (<1%) 0 Pancreatitis 1 (<1%) 0 Prostate cancer 1 (<1%) 0 Subcutaneous nodule 1 (<1%) 0 *Events of hypoglycaemia are described separately. Table 3: Treatment-emergent adverse events